LIXTE's LB-100 Shows Favorable Ovarian Cancer Trial Results, Expands Cohort
LIXT has more than doubled off its 52-week low of $0.64 on elevated volume (2.1× avg).
Summary
LIXTE Biotechnology announced favorable preliminary results from its clinical trial combining its lead compound LB-100 with Dostarlimab for ovarian clear cell carcinoma. The interim analysis of 20 patients showed an acceptable safety profile, a 40% disease control rate, and 6-month and 12-month overall survival probabilities of 0.84 and 0.69, respectively. This positive development follows a recent 10-K filing (2026-03-31) that included an auditor's 'going concern' warning and mentioned clinical trial setbacks, making this positive data particularly impactful. The favorable results have led to the enrollment of an additional cohort of 21 patients, indicating confidence in the drug's potential and building on a previous announcement (2026-03-31) regarding the trial's expansion. For a small clinical-stage biotech, positive data for a lead compound in a challenging disease is a significant catalyst and could help address the financial concerns highlighted in the recent annual report. Investors will monitor the progress of the expanded cohort and future data readouts, as well as any impact on the company's financial outlook.
At the time of this announcement, LIXT was trading at $2.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.4M. The 52-week trading range was $0.64 to $6.26. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.